Jefferies Starts ArriVent BioPharma (AVBP) at Buy, 'ArriVing with De-Risked Asset for Lung Cancer Treatment'
Tweet Send to a Friend
(Updated - February 20, 2024 3:55 AM EST)
Jefferies analyst Kelly Shi initiates coverage on ArriVent BioPharma (NASDAQ: AVBP) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Jefferies analyst Kelly Shi initiates coverage on ArriVent BioPharma (NASDAQ: AVBP) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
